Ashland Inc. to highlight controlled-release research at pharmaceutical industry symposium
(Thomson Reuters ONE) -
WILMINGTON, Del. - Solutions to three significant challenges faced by
controlled-release-system formulators are the focus of research posters from
Ashland Aqualon Functional Ingredients, a commercial unit of Ashland Inc. (NYSE:
ASH). The posters will be showcased at the Controlled Release Society's annual
meeting July 30 - Aug. 3 in National Harbor, Md.
The research presents solutions for the following challenges:
* How to adequately retard the delivery of high doses of highly soluble active
pharmaceutical ingredients (APIs);
* How to solubilize poorly water-soluble APIs; and
* How to avoid any dose-dumping tendency due to co-administration of alcoholic
beverages.
"Our research reveals that high-dose (75 percent), controlled-
release tablets of highly soluble drugs like metformin and acetaminophen can be
made by hot-melt extrusion granulation with cellulosic excipients such as
Klucel(TM) hydroxpropylcellulose (HPC) and Aqualon(TM) ethylcellulose(EC). In
addition, tablets from these granules showed exceptional compactability and
strength as compared with tablets made by traditional methods," said Laurie
Kronenberg, new product leader, Food and Pharmaceutical, Ashland Aqualon
Functional Ingredients.
A second research project featured by Ashland at the conference
focuses on matrix tablets formulated with Ashland's Klucel HPC or with
Benecel(TM) hypromellose (HPMC) that demonstrates no alcohol-induced dose
dumping, which is a growing safety and efficacy issue.
The final poster highlights a collaborative research project between
Ashland and scientists from the Pharmaceutics Department at the University of
Mississippi on the delivery of low soluble APIs via hot-melt extrusion with
Klucel HPC polymer combinations. "We are extremely pleased to work with Dr.
Michael Repka and others at the university to advance the research in delivery
technologies for poorly soluble APIs," added Kronenberg.
Ashland Aqualon Functional Ingredients will have representatives at
booth 619 during the meeting exposition hours. To learn more about Ashland's
pharmaceutical and nutraceutical products, please visit www.ashland.com, or
contact an Ashland representative by phone at 1-877-546-2782.
Ashland Aqualon Functional Ingredients is a global leader in cellulose ether
technology. Delivering pharmaceutical and nutraceutical performance since the
1950s, Functional Ingredients provides a range of functional excipients for
solid, semi-solid and liquid dosage forms. Functional Ingredients creates value
for its customers through applications knowledge, market insight, regulatory
support and a powerful product portfolio: Klucel HPC, Benecel methylcellulose
and HPMC, Aquarius(TM) coatings systems, Natrosol(TM) hydroxyethylcellulose,
Aqualon EC, and Aqualon and Blanose(TM) carboxymethylcellulose.
In more than 100 countries, the people of Ashland Inc. (NYSE: ASH) provide the
specialty chemicals, technologies and insights to help customers create new and
improved products for today and sustainable solutions for tomorrow. Our
chemistry is at work every day in a wide variety of markets and applications,
including architectural coatings, automotive, construction, energy, personal
care, pharmaceutical, tissue and towel, and water treatment. Visit
www.ashland.com to see the innovations we offer through our four commercial
units - Ashland Aqualon Functional Ingredients, Ashland Hercules Water
Technologies, Ashland Performance Materials and Ashland Consumer Markets
(Valvoline).
- 0 -
(TM)Trademark of Ashland or its subsidiaries, registered in various countries
FOR FURTHER INFORMATION:
Media Relations
Ken Gordon
614-790-1832 kdgordon(at)ashland.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ashland Inc. via Thomson Reuters ONE
[HUG#1530192]
Unternehmensinformation / Kurzprofil:
Datum: 12.07.2011 - 15:35 Uhr
Sprache: Deutsch
News-ID 56336
Anzahl Zeichen: 4868
contact information:
Town:
Covington
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 365 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ashland Inc. to highlight controlled-release research at pharmaceutical industry symposium"
steht unter der journalistisch-redaktionellen Verantwortung von
Ashland Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
